T cell-Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing. 2024

Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
Genentech Research and Early Development, Genentech Inc., South San Francisco, California.

T cell-retargeting therapies have transformed the therapeutic landscape for hematologic diseases. T cell-dependent bispecific antibodies (TDB) function as conditional agonists that induce a polyclonal T-cell response, resulting in target cell destruction and cytokine release. The relationship between this response and its effects on surrounding innate immune populations has not been fully explored. Here we show that treatment with mosunetuzumab in patients results in natural killer (NK) cell activation in the peripheral blood. We modeled this phenomenon in vitro and found that TDB-mediated killing activated NK cells, increasing NK function and antibody-dependent cellular cytotoxicity (ADCC), and enhanced the capability of macrophages to perform antibody-dependent cellular phagocytosis (ADCP). This enhancement was triggered by cytokines released through TDB treatment, with IL2 and IFNγ being major drivers for increased ADCC and ADCP, respectively. Surprisingly, cytolytic ability could be further augmented through neutralization of IL10 for NK cells and TNFα for macrophages. Finally, we showed that TDB treatment enhanced the efficacy of Fc-driven killing to an orthogonal solid tumor target in vivo. These results provide rationale for novel antibody therapy combinations that take advantage of both adaptive and innate immune responses.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D018033 Antibodies, Bispecific Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors. Bifunctional Antibodies,Bispecific Antibodies,Bispecific Monoclonal Antibodies,Antibodies, Bifunctional,Antibodies, Bispecific Monoclonal,Monoclonal Antibodies, Bispecific

Related Publications

Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
August 2019, Journal of immunology (Baltimore, Md. : 1950),
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
October 2019, Journal of immunology (Baltimore, Md. : 1950),
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
May 2004, Proceedings of the National Academy of Sciences of the United States of America,
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
April 2015, Oncoimmunology,
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
December 2021, Journal of hematology & oncology,
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
October 1995, Journal of hematotherapy,
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
February 2014, Journal of molecular medicine (Berlin, Germany),
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
July 2021, Scientific reports,
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
February 2019, Biochemical and biophysical research communications,
Rickvinder Besla, and Elicia Penuel, and Geoff Del Rosario, and Ely Cosino, and Szymon Myrta, and Mike Dillon, and Greg A Lazar, and Dorothee Nickles, and Christoph Spiess, and Shang-Fan Yu, and Andrew G Polson
March 2020, Infectious microbes & diseases,
Copied contents to your clipboard!